Beneficial Potential of Banha-Sasim-Tang for Stress-Sensitive Functional Dyspepsia via Modulation of Ghrelin: A Randomized Controlled Trial

Sul-Ki Kim†, Jin-Yong Joung†, Yo-Chan Ahn², In-Chul Jung³ and Chang-Gue Son¹*

¹Liver and Immunology Research Center, College of Korean Medicine, Daejeon University, Daejeon, Republic of Korea, ²Department of Health Service Management, Daejeon University, Daejeon, Republic of Korea, ³Departments of Neuropsychiatry, College of Korean Medicine, Daejeon University, Daejeon, Republic of Korea

Background: Functional dyspepsia (FD) is a highly complex pathophysiologic disease, which shows low recovery and high relapse rates. Therefore, a growing number of clinicians and patients are looking for alternative herbal medicine. Banha-Sasim-Tang (BST) is an herbal prescription for treating a wide range of dyspepsia in traditional Korean medicine (TKM).

Aim of the study: This study aimed to evaluate the efficacy of BST on FD in patients with psychological stress-related symptoms and to investigate the involvement of ghrelin. This study is registered at https://cris.nih.go.kr/ with the identification number KCT 0002811.

Materials and methods: A total of 31 participants with FD who met the Rome IV criteria and the psychological stress-related pattern were enrolled in a double-blind, randomized, and controlled study. Participants were randomly assigned to the BST group (10 g twice daily for 4 weeks) or placebo group. The primary endpoint was a change in the Nepean Dyspepsia Index–Korean (NDI-K) score. The secondary endpoints were changes in the Visual Analog Scale (VAS) scores and plasma ghrelin level.

Results: All participants completed the study (n = 15 for BST, n = 16 for placebo). BST decreased NDI-K scores compared with placebo, but the difference was not statistically significant (37.40 ± 27.40 vs 22.50 ± 23.85, p = 0.12). VAS scores and plasma total ghrelin levels were significantly improved in patients who were treated with BST (3.19 ± 1.60 vs 1.38 ± 2.85, p = 0.03 for VAS and 105.69 ± 287.89 vs -142.31 ± 314.32, p = 0.03 for total ghrelin). No BST-related adverse effects were observed during the trial.

Conclusion: Our results indicate the clinical potential of BST for FD patients and are the first study to show the modulation of plasma ghrelin as one of its corresponding mechanisms.

Clinical Trial Registration: https://cris.nih.go.kr/, identifier KCT 0002811.

Keywords: functional dyspepsia, banha sasim-tang, herbal medicine, ghrelin, clinical trial
INTRODUCTION

Functional dyspepsia is a recurrent or persistent dyspeptic symptom group that lasts more than 6 months but does not have explainable organic causes (Stanghellini et al., 2016). Several pathogeneses of FD have been reported, such as Helicobacter pylori or other infections, visceral hypersensitivity, low-grade mucosal inflammation, delayed gastric emptying (Talley and Walker, 2019). This highly complex pathology limits conventional therapy, and a growing number of clinicians and patients are alternatively looking for herbal medicine from a personalized and multitarget medical outlook (Chiariioni et al., 2018).

Banha-Sasim-Tang, also known as Banxia-Xiexin-Tang in traditional Chinese medicine and Hange-Shashin-To in Kampo medicine, is a traditional herbal medicine that has widely been used for treating gastrointestinal disease in traditional Korean medicine (Fan et al., 2019). Several clinical studies have shown the beneficial effects of BST against gastric dyspepsia and esophageal reflux symptoms (Gan et al., 2014; Shin et al., 2017). In particular, a preclinical study showed that BST-derived improvement in gastric emptying capacity might be linked to activated secretion of ghrelin, a peptide hormone known to promote appetite (Klok et al., 2007; Wu et al., 2014). Clinical studies presented the lowered plasma levels of ghrelin in patients with FD (Takakazu et al., 2013; Choi et al., 2017). Accordingly, we supposed that the underlying mechanism of BST on relieving FD symptoms comes by modulating ghrelin.

In practices of TKM/TCM, clinicians have adapted the pattern identification in processes of diagnosis and treatment for certain disorders including FD, which stresses the cluster of symptoms with its affecting factors (Ko et al., 2014). FD has generally divided into two subgroups as postprandial distress syndrome (PDS) and epigastric pain syndrome (EPS) (Houte et al., 2020), in conventional medicine, while TKM/TCM generally classify FD into six different identifications (Kim et al., 2010). Of those, the “liver Qi invading stomach (肝气犯胃)” pattern is most common in Korean FD patients (approximately 52.9%) (Park et al., 2008). This pattern is characterized by psychological stress-related factors that induce or accelerate the FD symptoms, including epigastric distension and pain extending to sides, belching, sighing, or nausea (Zhao et al., 2018, detail in Supplementary Tables S1, S2). In fact, stress is one of the key inducers of FD symptoms, and an anti-stress strategy is the main management approach for FD patients (Labanski et al., 2020).

On the other hand, the objective assessment of symptom severity frequently becomes an important issue especially for subjective disorders likely FD (McColl, 2004). Many instruments have been developed, but Nepean Dyspepsia Index has been mostly used as a validated questionnaire evaluating dyspepsia-specific symptoms and related quality of life (Talley et al., 1999). The Korean version of NDI has been validated (Lee et al., 2003) and properly adapted in various FD-related clinical trials in Korea (Yoon et al., 2018; Park et al., 2019). One clinical study reported the FD prevalence of approximately 25% of the general population, whose average of NDI-K score was 51.06 ± 29.64 (Ko et al., 2018).

In this study, we aimed to evaluate the efficacy and safety of BST in the FD patient having “liver Qi invading stomach (肝气犯胃)” pattern and to investigate its underlying mechanism related to ghrelin.

MATERIALS AND METHODS

Participants

Participants who met the following key eligibility criteria were included: age between 19 and 65 with a diagnosis of FD, moderate or severe degree according to the Rome IV criteria and corresponding to “liver Qi invading stomach” pattern (Table 1). The pattern identification including “liver Qi invading stomach” was determined using a questionnaire which was developed in 2010 in Korea (Kim et al., 2010). Briefly, FD patient belongs to one of six patterns by the highest sum score weighted for 33 symptom-related questions and clinician-derived diagnosis. Details of pattern identification and weight scores are shown in Supplementary Tables S1, S2. Also, participants were included if he/she had at least two symptoms of 2 (moderate) or 3 (severe) score with total score ≥6 points using the short form of NDI-K. The short form of NDI-K was modified from the original NDI-K; using key 8 items of 15 and scoring 0 (no symptom) to 3 (severe), respectively (Supplementary Table S3). The cut-off score (total score ≥6) has been decided by our research team based on the previous study results, which reported the total score ≥6 is enough for the moderate level of FD complaining (Fraser et al., 2007). The key exclusion criteria were participants who had organic abnormalities in gastric endoscopy. Participants currently using or who had used nonsteroidal anti-inflammatory drugs (NSAIDs) or corticosteroids were excluded. Details of the inclusion and exclusion criteria are provided in Table 1. The protocol was approved by the institutional review board (IRB) at Daejeon Korean Medicine Hospital (IRB number: DJSKH-17-DR-25-2). And this study is registered at https://cris.nih.go.kr/with the identification number KCT 0002811.

Trial Design and Intervention

This study was a double-blind, placebo-controlled, randomized, single-center trial. Participants were randomly assigned at a 1:1 ratio to receive 10 g of BST at once and orally took twice a day or matching placebo for 4 weeks, with a 2 weeks follow-up period without treatment (Figure 1). The random allocation number was handled by independent statistical experts and blocked random assignments were used. Every 2 weeks after taking BST or placebo, any unconsumed medications were returned to ensure medication adherence.

BST and placebo were prepared in syrup form by Jeong-Woo Pharmaceutical Company Ltd. according to Korean Good Clinical Practice guideline. BST consists of 7 different types of TKM-derived herbs (Table 2). Briefly, seven herbal materials were extracted by boiling water, and extracts were filtered, concentrated, and lyophilized. Molecular fingerprinting of BST (Figure 2) was performed using a high-performance liquid
chromatography system (HPLC, Agilent 1,100 system, CA, United States) equipped with an autosampler (G11313A), column oven (GA1316A), binary pump (G1312), diode-array-detector (DAD), and degasser (GA1379A) as described previously. A matching placebo was prepared in a form, flavor, and fragrance very similar to BST and contained corn starch, caramel pigment, etc. (Table 2). The participants were provided the trial drugs labeled with the number of the trial protocol (DJOMCBST-201701), product name (BST or placebo), batch number (803), expiration date (2021.02.18), address, contact

| TABLE 1 | Inclusion and exclusion criteria. |
|-----------------|----------------------------------|
| **The inclusion criteria are as follows** | |
| 1) participants who are 19–65 years old | |
| 2) participants who verified no evidence of structural disease through endoscopy within the last 24 months | |
| 3) participants who meet the functional dyspepsia according to rome IV criteria (criteria fulfilled for the last 3 months with symptom onset at least 6 months before diagnosis, more than one of the followings) | |
| A. Bothersome postprandial fullness | |
| B. Bothersome early satiation | |
| C. Bothersome epigastric pain | |
| D. Bothersome epigastric burning | |
| 4) participants who meet the “liver qi invading stomach” with Korean medicine pattern identification (see Supplementary Tables S1, S2) | |
| 5) participants who have at least two moderate symptoms or more than the total score of 6 among the 8 items of short form of NDI-K. (See Supplementary Table S3) | |
| **The exclusion criteria are as follows** | |
| 1) participants with a history of gastrointestinal surgery (except for appendectomy) | |
| 2) participants at risk of gastrointestinal motility, including gastrointestinal bleeding, mechanical intestinal obstruction, or perforation, etc | |
| 3) participants with diseases that may affect evaluation of efficacy in the previous 2 years | |
| For example, gastroduodenal ulceration, gastric cancer, or colorectal cancer, etc | |
| 4) participants who need anti-bactericidal treatment or are under anti-bactericidal treatment for H. pylori | |
| 5) participants who have taken medication affecting evaluation of trial medication efficacy within 1 month before the screening visit | |
| For example, glucocorticosteroids, nonsteroidal anti-inflammatory drugs, or prokinetics, etc | |
| 6) participants whose AST or ALT is more than 2 times the upper limit of normal, or creatinine is more than 1.2 times the upper limit of normal | |
| 7) woman who are pregnant or lactating | |
| 8) participants who have participated in other clinical trials and taken clinical trial medication within the last 3 months | |

NDI-K: Nepean dyspepsia index-Korean, AST: Aspartate aminotransferase, ALT: Alanine aminotransferase

| FIGURE 1 | Study flow diagram. |
The primary endpoint was the change in the NDI-K score, and changes in Visual Analogue Scale scores as a secondary endpoint. These measurements were assessed at time points of baseline, 4 weeks treatment and 2 weeks follow-up, respectively. In addition, we measured the plasma levels of acyl-ghrelin, des-acyl-ghrelin, and total ghrelin. At both time points of the baseline and of the one day after the last drug taken, venipunctures were conducted under an 8 h fasting state. The blood samples were used for liver and kidney function tests, and complete blood cell count test to ensure stability for medication as well as for measurement of ghrelin. One part of the blood sample was collected at 3.5 ml SST tube (BD Vacutainer®) and left at room temperature for 30 min for plasma ghrelin level analysis. Samples were centrifuged at 3,000 rpm for 20 min and dispensed 0.5 ml each for primary and back-up tubes. The tubes were stored at ~80°C and sent to one external institution (SML Meditree Co., Ltd., Seoul, Korea) for determinations of plasma ghrelin levels using a human acyl-ghrelin ELISA kit (Abbexa®) and human des-acyl-ghrelin ELISA kit (MyBioSource.Inc.).

### Sample Size Estimation

This study aimed to assess the efficacy of BST in patients with FD. The formula for estimating the sample size for each arm is as follows:

\[
\text{Sample Size} = \frac{2 \times \text{Z}_{\alpha/2} \times \text{Z}_{\beta} \times \text{SD}}{\Delta^2}
\]

where:
- \( \text{Z}_{\alpha/2} \) is the standard normal deviate for the chosen significance level (usually 0.05 for a two-tailed test).
- \( \text{Z}_{\beta} \) is the standard normal deviate for the chosen power (usually 0.80).
- \( \text{SD} \) is the standard deviation of the outcome measure.
- \( \Delta \) is the minimum detectable difference.

### Table 2

| Scientific name | Amount (g) | Scientific name | Amount (g) |
|-----------------|------------|-----------------|------------|
| Pinellia ternate (thunb.) makino | 1.18 | Corn starch | 1.92 |
| Scutellaria baicalensis georgi | 0.84 | Caramel pigment | 0.08 |
| Panax ginseng C.A. Meyer | 0.80 | Beta-cyclodextrin | 1.50 |
| Glycyrrhiza uralensis Fisch | 0.73 | Apple concentrate | 1.35 |
| Zingiber officinale roscoe | 0.58 | Sodium carboxymethyl cellulose | 0.05 |
| Coptis chinensis franch | 0.13 | Sodium benzoate | 0.01 |
| Ziziphus jujuba mill | 0.51 | Purified water | Suitable amount |
| Beta-cyclodextrin | 1.50 | Placebo | |
| Apple concentrate | 1.35 | Beta-cyclodextrin | 1.50 |
| Sodium carboxymethyl cellulose | 0.05 | Apple concentrate | 1.35 |
| Sodium benzoate | 0.01 | Sodium carboxymethyl cellulose | 0.05 |
| Purified water | Suitable amount | Sodium benzoate | 0.01 |
| Total | 10.00 | Purified water | Suitable amount |

### Figure 2

Molecular fingerprinting of Banha-Sasim-Tang.

number of the principal investigator, and precaution “Keep out of reach of children.”

Assessment

The primary endpoint was the change in the NDI-K score, and the changes in Visual Analogue Scale scores as a secondary endpoint. These measurements were assessed at time points of baseline, 4 weeks treatment and 2 weeks follow-up, respectively. In addition, we measured the plasma levels of acyl-ghrelin, des-acyl-ghrelin, and total ghrelin. At both time points of the baseline and of the one day after the last drug taken, venipunctures were conducted under an 8 h fasting state. The blood samples were used for liver and kidney function tests, and complete blood cell count test to ensure stability for medication as well as for measurement of ghrelin. One part of the blood sample was collected at 3.5 ml SST tube (BD Vacutainer®) and left at room temperature for 30 min for plasma ghrelin level analysis. Samples were centrifuged at 3,000 rpm for 20 min and dispensed 0.5 ml each for primary and back-up tubes. The tubes were stored at ~80°C and sent to one external institution (SML Meditree Co., Ltd., Seoul, Korea) for determinations of plasma ghrelin levels using a human acyl-ghrelin ELISA kit (Abbexa®) and human des-acyl-ghrelin ELISA kit (MyBioSource.Inc.).

### Sample Size Estimation

This study aimed to assess the efficacy of BST in patients with FD. The formula for estimating the sample size for each arm is as follows:
The average change in the NDI-K symptom score was assumed to be 17.40 considering the appropriate sample size, according to the average change value of previous studies 20.87 (Cho et al., 2004; Lee et al., 2013; Kim et al., 2014). The standard deviation (δ₀) of the amount of change was assumed to be 21.5, which is a common standard deviation value considering the number of samples according to previous study results (Cho et al., 2004; Lee et al., 2013; Kim et al., 2014). With a statistical power of 80% and a significance level (α) at 5%, 24 patients were required for each study arm. Assuming 20% of patients would drop out or be lost to follow-up, this study would recruit 30 participants to each group, totaling 60 participants.

Statistical Analysis
The analysis was conducted on the intention-to-treat (ITT) population, which included all participants who completed the baseline assessment and received at least one dose of the study drug in the treatment phase but excluded participants who did not receive any study medications for various reasons. A safety analysis was performed on all participants who received at least one dose of the trial medication. The continuous variables, including the primary endpoints, were compared using an independent t-test. Categorical variables such as demographic characteristics were compared using Pearson’s chi-square test or Fisher’s exact test. The changes in variables over time within each group were compared using a paired t-test. Statistical significance was indicated by a p-value less than 0.05.

RESULTS
Study Population
This study was conducted from June 2018 to November 2019. Thirty-six consecutive participants who fulfilled the inclusion criteria were initially enrolled; however, five participants withdrew consent due to personal reasons before starting the first drug administration. In total, 31 participants (11 male and 20 female) were included in the ITT analysis, of which 15 were assigned to receive BST and 16 to receive a placebo. The baseline demographics and clinical characteristics were similar between the two trial groups (Table 3). All participants included in the ITT analysis completed a 4 weeks clinical trial with greater than 75% adherence.

Changes in Endpoints
At baseline, the mean parameters of FD symptoms were uniformly distributed in both the BST and placebo groups: NDI-K (79.60 ± 20.14 vs 81.07 ± 30.28), VAS (7.57 ± 1.60 vs 7.48 ± 1.63 cm), and total ghrelin (620.61 ± 429.04 vs 515.37 ± 488.65 pmol/L), respectively (Table 3). After 4 weeks treatment, the BST group showed more improvement in NDI-K score (37.40 ± 22.50 vs. 22.50 ± 23.85) than the placebo group (but not statistically significant, p = 0.12), while the change of the VAS score was significant (3.62 ± 2.00 vs 1.87 ± 2.57, p = 0.04), (Supplementary Table S4). Also, plasma total ghrelin levels were significantly increased in the BST group compared to the placebo group (105.69 ± 68.25 pmol/L vs −142.31 ± 314.32 pmol/L, p = 0.03) (Figure 3C). BST treatment also increased both acyl and des-acyl-ghrelin levels, but they were not significant compared to the placebo group (12.29 ± 81.07 vs −74.56 ± 223.54 pmol/L in acyl-ghrelin, p = 0.16, and 93.40 ± 275.42 vs. −67.74 ± 226.01 pmol/L in des-acyl-ghrelin, p = 0.09), respectively (Figure 3C).

Safety
One participant (6.7%) in the BST group and two participants (12.5%) in the placebo group presented some adverse events: a 65-year-old male with hematuria (urine occult blood 2+) during BST administration, while two cases of hyperbilirubinemia in a 61 year-old female (total bilirubin 1.56 mg/dl) and 38 year-old male (total bilirubin 1.54 mg/dl) in the placebo group. They all recovered over a monitoring period of 2 weeks without any treatment. No statistical correlation was observed in those adverse events with BST.
**DISCUSSION AND CONCLUSION**

FD is a representative multifactorial and complicated pathologic disease, and various approaches have been attempted in conventional therapy, such as proton pump inhibitors (PPIs), prokinetics, and tricyclic antidepressants (TCAs) (Ahmed et al., 2018). However, these current therapeutics have many limitations including the high relapse rate up to 73% (Talley et al., 2014). As an alternative intervention, 3 clinical studies have been conducted on the effect of BST on FD to date (Yoon et al., 2003; Park et al., 2013; Zhao et al., 2013). Then, interestingly, clinical outcomes were more effective when pattern identification was adapted (Zhao et al., 2013) than when it was not adapted (Park et al., 2013). Pattern identification diagnosis and herbal prescription have received attention as personally tailored and multi-targeted medicines, especially in multifactorial diseases, in which conventional medicine already has been revealed limitations (Chiarioni et al., 2018).

The present study is the first trial to evaluate BST as an FD medication by enhancing ghrelin, especially for patients with the pathologic pattern of “liver Qi invading stomach.” According to the TKM/TCM pathology theory, excessive liver Qi, which commonly occurs under psychological stress, can invade the stomach and disrupt its homeostasis (Ling et al., 2012). Under psychological stress, the brain autonomically down-regulates gastrointestinal peristalsis and enteric endocrine system by activating the sympathetic nervous system (SNS) via releasing norepinephrine and decreasing blood flow (Kirsteen et al., 2014; Andreas and Yvette, 2010). The altered appetite, a common symptom of FD, is also caused frequently by psychological stress (Asakawa et al., 2001). Because FD is a disease of dysfunctional status without any meaningful physical defects, psychological stress is one of the most likely causes (Nan et al., 2015). In addition, the psychological stress response is also known to be associated with the secretion of ghrelin from mainly in the stomach (Andreas et al., 2011; Chuang and Zigman, 2010). Some clinical studies clearly have shown that ghrelin stimulates upper
gastrointestinal motility (Tack et al., 2006) and circulating ghrelin levels could be altered by various stressors (Stengel et al., 2011). Our previous animal study found that BST modulates peristalsis via activation of the interstitial cells of Cajal and the smooth muscle cells in the stomach (Jeon et al., 2019). As we expected, BST administration notably improved the measurements of FD (Figures 3A,B). The lack of statistical significance in NDI-K might have resulted from the small number of participants. Although NDI-K just showed the tendency without statistical significance, VAS is known as a more intuitive evaluation instrument directly related to participants’ treatment satisfaction (Domenica et al., 2018).

On the other hand, BST administration significantly increased the plasma level of total ghrelin (Figure 3C). Ghrelin is a peptide hormone that is produced mainly by enteroendocrine cells of the stomach and stimulates appetite, gastrointestinal motility, and gastric acid secretion (Koji et al., 2008; Camilleri et al., 2009). Clinical studies showed lower levels of plasma total ghrelin in FD patients than in healthy volunteers (Lee et al., 2009). A significant increase in energy intake was observed with ghrelin infusion in cancer patients (Nicola et al., 2004). The intravenous administration of ghrelin promoted gastric emptying in diabetic gastroparesis patients (Murray et al., 2005). Usually, ghrelin exists in two forms, acyl-ghrelin and des-acyl-ghrelin, which are known to be active and inactive, respectively (Delporte, 2013). In our results, acyl-ghrelin and des-acyl-ghrelin were both notably increased in BST compared to placebo, but without statistical significance comparing to the placebo group. Yukgunja-Tang (六君子汤), another popular herbal prescription for FD patients with a Qi (氣) deficiency pattern, also increased serum ghrelin levels as its proposed mechanism of action (Fujitsuka and Uezono, 2014). Then, Pinellia ternate (Thunb) Makino, Panax ginseng C.A. Meyer, Zingiber officinale Roscoe, Glycyrrhiza uralensis Fisch, and Ziziphus jujuba Mill overlap in preparations of both BST and Yukgunja-Tang. Also, P. ternate, P. ginseng, and Z. officinale directly elevated ghrelin levels in animal models (Lee and Baik, 2019). The above facts strongly suggest the modulation of ghrelin as one of the corresponding mechanisms in the improvement of FD by BST. However, the plasma ghrelin level in FD patients is still a little bit controversial. Another study reported a higher plasma ghrelin level in FD patients than in healthy volunteers (Lanzini et al., 2006).

This study has some limitations. First, we could not achieve the full recruitment of participants because of a lack of time and resources due to the investigator-initiated trial. So, the number of participants was relatively small, which might lead to the lack of statistical significance in the NDI-K score. In addition, this small number of participants gave us difficulty to analyze the gender- or age-related response rates. Second, blinding might be incomplete; likely the difference between the BST group (13/15, 86.7%) and the placebo group (6/16, 62.5%) answered the receiving BST.

Despite some limitations, this trial was the first study to claim a potential association between BST and plasma ghrelin levels in FD patients. It would be very worth finding that BST acts as a modulator of gastrointestinal ghrelin in functional dyspeptic disorders. This potential relationship should be further explored in larger studies.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material, further inquiries can be directed to the corresponding authors.

ETHICS STATEMENT

The protocol was approved by the Institutional Review Board (IRB) at Daejeon Korean Medicine Hospital (IRB number: DJDSKH-17-DR-25-2). The patients/participants provided their written informed consent to participate in this study.

AUTHOR CONTRIBUTIONS

SKK and JYJ were major contributors to the data analysis and wrote the first draft of the manuscript. YCA performed a statistical analysis. ICJ revised the manuscript. CGS was responsible for supervision of the study and contributed to designing and writing the final version of manuscript. All the authors read and approved the final manuscript.

FUNDING

This study was supported by a grant of the traditional Korean Medicine R and D Project, Ministry of Health and Welfare (HI15C0006), and by the National Research Foundation of Korea (NRF-2018R1A6A1A03025221), Republic of Korea.

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2021.636752/full#supplementary-material.

REFERENCES

Ahmed, M., Viola, A., Paul, E., Joachim, L., Thomas, F., and Schemann, M. (2018). The Diagnosis and treatment of functional dyspepsia. Dtsch Arztebl Int. 115, 222–232. doi:10.3238/arztebl.2018.0222

Andreas, S., Lixin, W., and Yvette, T. (2011). Stress-related alteration of acyl and desacyl ghrelin circulating levels: mechanisms and functional implications. Peptides 32 (11), 2208–2217. doi:10.1016/j.peptides.2011.07.002

Andreas, S., and Yvette, T. (2010). Neuroendocrine control of the gut during stress: corticotropin-releasing factor signaling pathways in the
spotlight. Amnu. Rev. Physiol. 71, 219–239. doi:10.1146/annurev.physiol.010908.163221
Asakawa, A., Imaz, A., Kaga, T., Yuzurihisa, H., Nagata, T., Fujimiya, M., et al. (2001). A role of ghrelin in neuroendocrine and behavioral responses to stress in mice. Neuroendocrinol. 74 (3), 143–147. doi:10.1002/0005034680
Camilleri, M., Papathanasopoulos, A., and Odunsi, S. T. (2009). Actions and therapeutic pathways of ghrelin for gastrointestinal disorders. Nat. Rev. Gastroenterol. Hepatol. 6, 343–352. doi:10.1038/nr gastro.2009.72
Chiarioni, G., Pesce, M., Fantin, A., and Sarnelli, G. (2018). Complementary and alternative treatment in functional dyspepsia. United Eur. Gastroenterol. J. 6, 5–12. doi:10.1177/2050641617724061
Choi, Y. J., Park, Y. S., Kim, Y. S., Lee, S. M., Kim, N., Lee, D. H., et al. (2017). Gender differences in ghrelin, nociception genes, psychological factors and quality of life in functional dyspepsia. Wg 23, 8053–8061. doi:10.2145/wg.v24i5.8053
Chuang, J. C., and Zigman, J. M. (2010). Ghrelin levels and their relationship with gastric emptying in patients with dysmotility-like functional dyspepsia. Digestion 80, 58–63. doi:10.1159/000215389
Lee, S.-h., and Baik, T.-H. (2019). A comparative study on the effects of Pinellia ternata, zingerib officinar and sobanhotang on reflux esophagitis. J. Korean Med. 40, 17–34. doi:10.1177/2050640617724061
Delporte, C. (2013). Structure and physiological actions of ghrelin. Scientifica. 20138099. doi:10.1155/2013/20138099
Domenica, A. D., Bradley, S. L., Nickolas, B. P., Patrick, C. M., Andrew, B. R., Moreno, M. P., et al. (2018). Validation of digital visual analog scale pain scoring with a traditional paper-based visual analog scale in adults. J. Am. Acad. Ortop. Surg. Glob. Res. Rev. 2, e088. doi:10.5341/jaabosglas-D-17-00088
Fan, M., Zhang, X., Liu, J., and Wang, S. (2019). Research progress in functional dyspepsia relevant to traditional Chinese medicine based on the theory of brain-gut Axis, Zhong Nan Da Xue Xue Bao Yi Xue Ban. 44, 1300–1305. doi:10.1187/ jns.1672-7347.2019.180548
Fraser, A., Delaney, B. C., Ford, A. C., Qume, M., and Moayyedi, P. (2007). The short-form leads dyspepsia questionnaire validation study. Aliment. Pharmacol. Ther. 25 (4), 477–486. doi:10.1111/j.1365-2036.2006.03233.x
Fujitsu, N., and Uezono, Y. (2014). Rakkumshito, a ghrelin potentiator, ameliorates anorexia-cachexia syndrome. Front. Pharmacol. 5, 271. doi:10.3389/fphar.2014.00271
Gan, Y., Yang, L., Liu, H., and Yang, K. (2014). Effect of banxaiexin tang on treatment of functional dyspepsia: a meta-analysis of randomized controlled trials. J. Traditional Chin. Med. 34 (2), 140–144. doi:10.10524/6272(14) 60067-4
Houe, K. V., Florenca, C., Nick, G., Jolien, S., Imke, M., Arts, J., et al. (2020). Effects of Rome IV definition of functional dyspepsia subgroups in secondary care. Clin. Gastroenterol. Hepatol.. 6, doi:10.1016/j.cgh.2020.06.043
Jeon, Y.-J., Cho, Y.-R., Lee, S.-B., Kim, W. Y., Lee, J. S., Roh, S.-S., et al. (2019). Banha-sasim-Tang improves gastrointestinal function in loperamide-induced functional dyspepsia mouse model. J. Ethnopharmacol. 238, 111834. doi:10.1016/j.jep.2019.111834
Kim, K. B., Kang, J. H., Son, C. G., and Kang, W. C. (2010). Development of instrument of pattern identification for functional dyspepsia. Journal Korean Oriental Phisiology Pathol. 24, 1094–1098.
Kim, J.-B., Shin, J.-W., Son, C.-G., and Lee, H.-W. (2014). A traditional herbal formula, Hyangsa-Pyeongwan san (HPS), improves quality of life (QOL) of the patient with functional dyspepsia (FD): randomized double-blind controlled trial. J. Ethnopharmacol. 151 (1), 279–286. doi:10.1016/j.jep.2013.10.033
Kirsteen, N.B., and Alberto, T. (2014). Central nervous system control of gastrointestinal motility and secretion and modulation of gastrointestinal functions. Compr. Physiol. 4 (4), 1339–1368. doi:10.1002/cphy.c130055
Klok, M. D., Jakobsdottir, S., and Drent, M. L. (2007). The role of leptin and ghrelin in the regulation of food intake and body weight in humans: a review. Obes. Rev. 8 (1), 21–34. doi:10.1111/j.1467-789x.2006.00270.x
Ko, M., Lee, J., Yun, K., You, S., and Lee, M. (2014). Perception of pattern identification in traditional medicine: a survey of Korean medical practitioners. J. Traditional Chin. Med. 34 (3), 369–372. doi:10.1016/j.tcm.2014.04.0104.7
Ko, S. J., Park, J. W., Lee, J. H., Lee, J. E., Ha, N. Y., Nam, S. U., et al. (2018). An herbal medicine, yokugun-tang is more effective in a type of functional dyspepsia categorized by facial shape diagnosis: a placebo-controlled, double-blind, randomized trial. Evid Based Complement Alternat Med. doi:10.1155/2018/8546357
Koji, Y., Junichi, K., and Shingo, K. (2008). Ghrelin and gastric acid secretion. World J. Gastroenterol. 7, 6334–6338. doi:10.3748/wjg.v14.i43.6334
Ko, S. J., Park, J. W., Lee, J. H., Lee, J. E., Ha, N. Y., Nam, S. U., et al. (2018). An herbal medicine, yokugun-tang is more effective in a type of functional dyspepsia categorized by facial shape diagnosis: a placebo-controlled, double-blind, randomized trial. Evid Based Complement Alternat Med. doi:10.1155/2018/8546357
multicenter, randomized controlled study. Gastroenterol. 149 (2), 340–e2. doi:10.1053/j.gastro.2015.04.020
Talley, N., and Walker, M. (2019). Emerging evidence that irritable bowel syndrome & functional dyspepsia are microbial diseases. Indian J. Med. Res. 149, 437–440. doi:10.4103/ijmr.ijmr_84_19
Togawa, K., Matsuzaki, J., Kobayakawa, M., Fukushima, Y., Suzuki, F., Kasugai, K., et al. (2015). Association of baseline plasma des-acyl ghrelin level with the response to rikkunshito in patients with functional dyspepsia. J. Gastroenterol. Hepatol. 31, 334–341. doi:10.1111/jgh.13074
Wu, J., Zhang, X. X., and Shen, H. (2014). Effect of Banxia xie xin decoction on gastric emptying and ghrelin in gastric antrum tissue with functional dyspepsia of rats. J. Sichuan Trad. Chi Med. 32, 70–72.
Yoon, H., Lee, D. H., Lee, Y.-H., Jeong, J. C., Lee, S. T., Choi, M. G., et al. (2018). Efficacy and safety of UI05MSP015CT in functional dyspepsia: a randomized, controlled trial. Gut and Liver 12 (5), 516–522. doi:10.5009/gnl17416
Yoon, S. H., Ryu, B. H., Ryu, K. W., and Kim, J. S. (2003). Evaluation for therapeutic effectiveness of banwhasashim-tang in functional dyspepsia. J. Int. Korean Med., 24, 329–336.
Zhao, L. Q., Zhang, S. S., Wang, Z. F., Wang, C. J., Huang, S. P., Shen, H., et al. (2013). Efficacy of modified ban xia xie xin decoction on functional dyspepsia of cold and heat in complexity syndrome: a randomized controlled trial. Evid Based. Comp. Alternat. Med. 812143. doi:10.1155/2013/812143
Zhao, L., Wang, T., Dong, J., Chen, A., and Li, G. (2018). Liver-stomach disharmony pattern: theoretical basis, identification and treatment. J. Traditional Chin. Med. Sci. 5, 53–57. doi:10.1016/j.jtcms.2018.01.001

Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Kim, Joung, Ahn, Jung and Son. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.